It is below NTA, but there is some uncertainty about how accurate the NTA is.However, what I don't like is that Challenger retain their units and don't accept the same deal that all other shareholders are being asked to accept.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%